Notably, human CD1c (BDCA-1)+ myDCs are heterogeneous, with a CD14-positive subpopulation that is immunosuppressive and a CD14-negative subpopulation that is capable of mediating antitumor immune responses induced by immunogenic cancer cell death [26,27,28]. The gene discussed is CD14; the disease is cancer.